Major South Korean pharmaceutical and biotech companies are set to participate in the world's largest pharmaceutical exhibition to expand global partnerships.
According to industry sources, key pharmaceutical and biotech firms will attend the CPHI Worldwide 2026, taking place in Milan, Italy, from October 6 to 8. This annual event, which rotates among major European cities, is recognized as a global business platform that covers the entire pharmaceutical value chain, including active pharmaceutical ingredients (APIs), finished pharmaceuticals, biopharmaceuticals, contract development and manufacturing organizations (CDMOs), and pharmaceutical equipment and technology.
This year, approximately 2,900 companies from over 160 countries are expected to participate, with more than 62,000 industry professionals anticipated to attend.
As global big pharma and major CDMO companies gather, South Korean firms plan to showcase their technological and production capabilities through dedicated booths and a Korean pavilion.
Lotte Biologics will operate a standalone booth and aims to secure CDMO contracts from global big pharma. The company will emphasize its 'Dual Site' competitiveness based on its facilities in Songdo and Syracuse, New York.
On the first and second days of the event, Lotte will conduct 'In-booth Presentations' to highlight its large-scale commercial production capabilities and strengths in bispecific antibodies. The company plans to actively promote its business structure connecting Korea and the U.S. and its commercial production competitiveness to attract customers.
Dongkuk Pharmaceutical will also have a standalone booth for the fifth consecutive year, focusing on its differentiated technology for the long-acting drug delivery platform, DK-LADs (Dongkook-Long Acting Delivery system).
At the event, the company plans to actively promote the Phase 3 clinical results of its prostate cancer treatment injection, Lorelin Depot, which features a three-month formulation (11.25mg). This product reduces the burden of hospital visits for patients by extending the dosing interval compared to the existing one-month formulation. Dongkuk aims to impress global partners with its platform technology that balances efficacy duration and patient convenience through DK-LADs.
Kolon Life Science will also participate with a standalone booth, showcasing its competitive high-quality raw materials and new portfolio, as well as integrated CDMO services to expand its global presence.
The company has received continuous quality audit approvals from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and local pharmaceutical companies, and has obtained GMP certification from Brazil's National Health Surveillance Agency (ANVISA), establishing a quality management system that meets strict global regulatory standards. At this exhibition, Kolon plans to unveil a range of new supply items targeting the rapidly growing RNA therapeutic market.
Focusing on its core raw material, phosphoramidite, Kolon will expand its lineup to include various modified phosphoramidites and customer-tailored development solutions to actively respond to rapidly changing market demands. In the CDMO sector, the company will introduce its 'customer-tailored manufacturing and quality management (CMC) solutions' that encompass process development, commercial production, and global regulatory compliance.
Lee Han-guk, CEO of Kolon Life Science, stated, "We will actively showcase our differentiated capabilities to meet the diverse needs of our customers."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.